Quick Answer
Upstream Bio, Inc. reported Operating Income Loss of -$160.36 million for the year ending 2025.
- Upstream Bio, Inc. showed a decrease of -106.2% in Operating Income Loss from 2024 to 2025.
- This data is from Upstream Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2023: -$9.39 million | Q1 2024: -$15.01 million | Q2 2024: -$17.54 million | Q3 2024: -$18.89 million | Q1 2025: -$32.01 million | Q2 2025: -$44.35 million | Q3 2025: -$37.83 million.
- Over the full 3 years of available data (2023 to 2025), Upstream Bio, Inc.'s Operating Income Loss has declined by 299.8%.
- Historical annual values: Fiscal year 2025: -$160.36 million | Fiscal year 2024: -$77.76 million | Fiscal year 2023: -$40.11 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: